Navigation Links
NW Bio Activates Second Site in DCVax-Direct Phase I/II Trial
Date:9/24/2013

BETHESDA, Md., Sept. 24, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that the MD Anderson Cancer Center Orlando has become the second site participating in the Phase I/II clinical trial of DCVax-Direct, the Company's next generation dendritic cell product for the potential treatment of all inoperable solid tumor cancers.

(Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO)

MD Anderson-Orlando is one of the predominant cancer centers in the Southeast United States. The wide range of cancers treated at the institution make it an excellent fit for this Phase I/II trial which is very broadly targeted, enrolling patients with all types of solid tumors for which surgery is not possible.

DCVax-Direct is a live cell product, composed of dendritic cells (the master cells of the immune system) activated in a proprietary way which may mobilize the natural immune system to reverse the growth of solid tumors, with the goal to kill the cancerous tumor cells and shrink the tumors. The product makes optimal use of the advanced manufacturing system that is proprietary to NW Bio and which delivers cells with maximum immune-activating capacity.

Unlike many other live cell products, the DCVax-Direct dendritic cells are injected directly into the tumor tissue where they begin to do their work.  Animal experiments have shown that this approach can potentially be highly effective in eliminating established tumors.  

MD Anderson-Orlando joins MD Anderson'/>"/>

SOURCE Northwest Biotherapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Baylor University Medical Center activates Allscripts electronic health record system
2. UBM Medica US Medical Diagnostic Game Makes Second Appearance on ConsultantLive
3. Apollo Medical Holdings Reports Record Fiscal 2014 Second Quarter Results
4. Access Pharmaceuticals Awarded Second European Patent for MuGard
5. Neurocrine Biosciences Announces the Start of Second Phase III Study of Elagolix in Endometriosis
6. China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2013 Financial Results
7. ConvaTec Announces 2013 Second Quarter Earnings Call
8. PRN Physician Recommended Nutriceuticals Selected for the Second Consecutive Year to the Inc. 500
9. 5000 List of Fastest-Growing Privately Held Companies
10. International Isotopes Inc. Announces Second Quarter and Six Months 2013 Financial Results
11. ULURU Inc. Reports Second Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Most osteoporosis patients want a choice in the medication ... by Mission Pharmacal Company. The survey, conducted by ... community, revealed that 74 percent of osteoporosis patients surveyed ... other than a pill or a tablet. ...
(Date:1/15/2014)... 15, 2014 AARP Foundation today announced it has established ... from the severe cold weather that has gripped much of ... those in need; so to support these emergency relief efforts ... $250,000, which could mean up to $500,000 in aid. The ...
(Date:1/15/2014)... THOUSAND OAKS, Calif. , Jan. 15, 2014 ... and Amgen (NASDAQ: AMGN ) announced ... to jointly discover and validate new therapeutic targets ... (IBD), a chronic disorder that affects millions worldwide. ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4
... Healthcare and,Laboratory Corporation of America(R) Holdings (LabCorp(R)) ... agreement to discuss future,possibilities to co-develop new ... diagnostics, metabolic syndrome, oncology and diabetes. Under ... new tests that,could make the biggest impact ...
... of the American Pain Society ... ... sustained pain relief from diabetic neuropathic pain (DNP),compared to placebo-treated patients, according ... (APS) in Tampa, Fla., "This is the first placebo-controlled trial of ...
Cached Medicine Technology:Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 2Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 3Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 4New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain 2New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain 3New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain 4
(Date:4/23/2014)... research, published in the journal Oncotarget , ... different appearances or their own DNA signatures within ... difficult to design effective, targeted treatment strategies. , ... EGFR mutation and either the KRAS or BRAF ... by the EGFR gene mutation have that specific ...
(Date:4/23/2014)... has been a rapidly evolving pursuit with many ... in the research road, scientists have found a ... with the disease. The report, which appears in ... have important implications for developing novel treatments. , ... that for years, research has suggested a link ...
(Date:4/22/2014)... device has been shown to reduce seizures in patients ... When coupled with an innovative electrode placement planning system ... complete elimination of seizures in nearly half of the ... , That,s good news for a large portion of ... epilepsy whose seizures can,t be controlled with medications and ...
(Date:4/22/2014)... at UT Southwestern Medical Center are making breakthroughs that ... A team of physician-scientists at UT Southwestern has ... with natural anti-depressant properties) works inside the brain. Simultaneously, ... depression in the form of a neuroprotective drug known ... in April,s issue of Molecular Psychiatry, is ...
(Date:4/22/2014)... for Molecular Pathology (AMP) released a report today ... on recommendations for a molecular diagnostics curriculum at ... The report was prepared by the Medical Laboratory ... Training and Education Committee. "Our goal was to ... laboratory scientists appropriately in order to manage the ...
Breaking Medicine News(10 mins):Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2Health News:Newly approved brain stimulator offers hope for individuals with uncontrolled epilepsy 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3Health News:AMP publishes curriculum recommendations for medical laboratory scientists 2
... WEST PALM BEACH, Fla., Aug. 25 For years, millions ... pantyhose to cover up unsightly varicose and spider veins. Now there,s ... Garden of Life,s ( www.gardeno f life.com ... clinical studies and millions of happy European women. , , ...
... ORLEANS, Aug. 25 Over 102,000 Americans are ... and a Slidell, Louisiana resident is making the most of his ... for the 2010 Transplant Olympics, twittering his progress, and furthering his ... a unique and personal level of hope and understanding by caring ...
... Study Suggests Division, Ambivalence and Hesitancy to Change; Demographics ... Aug. 25 Americans lack confidence that healthcare reform will deliver ... released today by the Thomson Reuters. , , ... a wide range of issues including the cost and quality of ...
... ... the aging eye , ... Francisco, CA (Vocus) August 25, 2009 -- EyeCare America, a national non-profit organization that provides ... a healthy aging eye in honor of September,s Save Your Sight Month., , , , ...
... ... of Honolulu are celebrating the fifth anniversary of their successful partnership by holding an ... ... healthcare education company, and Kapi,olani Community College of Honolulu are celebrating the fifth anniversary ...
... ... honest and forthright look at why Americans are overweight, overwhelmed, and confused, and ... ... (PRWEB) August 25, 2009 -- The question is not whether Americans are getting ...
Cached Medicine News:Health News:Garden of Life Launches Lovely Legs(TM) to Reduce Visible Signs of Varicose and Spider Veins 2Health News:Double Recipient Twitters Transplant Olympic Training and Tackles Nursing School 2Health News:Thomson Reuters Survey: Americans Skeptical that Healthcare Reform Will Improve Quality or Affordability 2Health News:Thomson Reuters Survey: Americans Skeptical that Healthcare Reform Will Improve Quality or Affordability 3Health News:EyeCare America Promotes Healthy Aging Tips During September's Save Your Sight Month 2Health News:EyeCare America Promotes Healthy Aging Tips During September's Save Your Sight Month 3Health News:EyeCare America Promotes Healthy Aging Tips During September's Save Your Sight Month 4Health News:Career Step and Kapi'olani Community College Celebrate Five Year Partnership 2Health News:The Naked Truth: Overweight, Overwhelmed and Confused 2
A full function instrument at an economical price....
... The ophthalmoscope with superior aspherical optics. ... by means of the aspherical optical system ... Beta 200 allows you to view the ... retina even with a small pupil. Conventional ...
The world's first automatic computation program analyzes massive amount of measurement data and computes "the most comfortable value" for the patient....
... Rx Master is designed and ... reliable service and give the ... improve procedures. It embodies the ... want most, including accuracy, speed, ...
Medicine Products: